Business
VMS Rehab Systems Inc.'s generic drug unit launches first private placement of class 'a' shares
VMS Rehab Systems Inc.'s generic drug unit launches first private placement of class 'a' shares.
About this update from Vms Rehab Systems
[{"type":"text","content":"\n\n\n\nVMS Rehab Systems Inc.'s generic drug unit launches first private placement of class 'a' shares\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVMS Rehab Systems Inc.'s generic drug unit launches first private placement of class 'a' shares\nPR Newswire\nOTTAWA, Ontario, June 8, 2016\n\n\n\nOTTAWA, Ontario, June 8, 2016 /PRNewswire/ -- The Board of Directors of VMS Rehab Systems Inc. reported today that its generic drug unit BioPharmcor B.V., launched this week its first private placement of class A voting shares. The Offering which has priced BioPharmcor B.V. ordinary A shares at eurocents 0.75 per share will be limited to 149 prospective investors. BioPharmcor B.V. has currently approximately 27 million common A shares outstanding at this time.\n\nAccording to Dawid Mrotek, BioPharmcor's Director of Investor Relations, \"BioPharmcor has a very exciting and focussed development program in place to develop a pipeline of generic drug products to improve Men's health. We have successfully funded our development program to date through a corporate bond program which we will continue to offer through our Poland based unit BioPharmcor Sp. z o.o.\"  Adds Mr Mrotek, \"We have taken note of the fact that there is a large contingency of investors who have an interest in investing in the shares of BioPharmcor B.V., the group's parent company. We anticipate that should we receive a strong demand for BioPharmcor shares in this initial round of the Company's private placement, we may well expand this funding strategy in conjunction with our debt offerings to address future requirements.\"\n\nThe BioPharmor Group is currently developing a generic tadalafil drug product which is recognized as a first line treatment for Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia (BPH). Proceeds from the Company's private placement offering will be used for further development work.\n\nEstablished in 2014, Amsterdam based BioPharmcor B.V., has two operating subsidiaries, BioPharmcor Sp. z o.o. in Warsaw, Poland and BioPharmcor Inc, in Ottawa, Canada.\n\nVMS Rehab Systems ...